Intubation secondary to asthma exacerbation in a patient with asthma receiving xolair (omalizumab)

Abstract

Pediatric PulmonologyVolume 43, Issue 1 p. 102-103 Letter to the EditorFree Access Intubation secondary to asthma exacerbation in a patient with asthma receiving xolair (omalizumab) Zachary D. Jacobs MD, Zachary D. Jacobs MD Pulmonary & Allergy Division, Department of Child Health, University of Missouri-Columbia, One Hospital Drive, Columbia, MissouriSearch for more papers by this authorJesus R. Guajardo MD, MHPE, Corresponding Author Jesus R. Guajardo MD, MHPE [email protected] Pulmonary & Allergy Division, Department of Child Health, University of Missouri-Columbia, One Hospital Drive, Columbia, MissouriPulmonary & Allergy Division, Department of Child Health, University of Missouri-Columbia, One Hospital Drive, Columbia, MO 65212.Search for more papers by this author Zachary D. Jacobs MD, Zachary D. Jacobs MD Pulmonary & Allergy Division, Department of Child Health, University of Missouri-Columbia, One Hospital Drive, Columbia, MissouriSearch for more papers by this authorJesus R. Guajardo MD, MHPE, Corresponding Author Jesus R. Guajardo MD, MHPE [email protected] Pulmonary & Allergy Division, Department of Child Health, University of Missouri-Columbia, One Hospital Drive, Columbia, MissouriPulmonary & Allergy Division, Department of Child Health, University of Missouri-Columbia, One Hospital Drive, Columbia, MO 65212.Search for more papers by this author First published: 28 November 2007 https://doi.org/10.1002/ppul.20703AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Hamilton RG, Marcotte GV, Saini S. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy. J Immunol Methods 2005; 303: 81– 91, 81. 2 Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725– 734. 3 Ayres JG, Higgins B, Chilvers ER, Ayer G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701– 708. 4 Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Della Cioppa G. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 302– 308, 303. 5 Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, Champain K, Fox H, Thirlwell J, Della Cioppa G. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20: 73– 78. 6 Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111: 87– 90, 88. 7 Hosegate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 17: 233– 240. 8 Humbert M, Beasley R, Ayres J. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309– 316. 9 Lanier B, Corren J, Lumry W, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91: 154– 159. 10 Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254– 261. Volume43, Issue1January 2008Pages 102-103 ReferencesRelatedInformation